Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 02, 2020 16:53 ET | Source: Asklepios BioPharmaceutical, Inc.

AskBio to Present at the 38th Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a fully integrated, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
December 19, 2019 08:25 ET | Source: Asklepios BioPharmaceutical, Inc.

AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease

– Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and...
April 25, 2018 08:05 ET | Source: Asklepios BioPharmaceutical, Inc.

Asklepios BioPharmaceutical, Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic

Pfizer, Inc. Dosed First Patient in its Mini-Dystrophin Gene Therapy Phase 1b Trial Another AskBio Platform Product to be Acquired by Big Pharma Novartis CHAPEL HILL, N.C., April 25, 2018 (GLOBE...